Boron neutron capture therapy (BNCT): Implications of neutron beam and boron compound characteristics
A comparison is made of the potential efficacy of boron neutron capture therapy (BNCT) for malignant glioma as a function of realistic epithermal-neutron beam biophysical characteristics and present and future boron compound biochemical characteristics. Monte Carlo analyses were performed to evaluate the relative significance of epithermal-neutron-source and boron-drug characteristics on theoretical tumour control using a standard model. No conclusions were intended regarding relative value of the three existing facilities. However, when a beam with optimal characteristics for all aspects is deployed (a technically realistic prospect), a significant gain in tumour control probability (TCP), relative to the existing facilities will result. New boron compounds are being developed with improved macroscopic and microscopic biodistribution characteristics. Calculations using assumed (but realistic) compound characteristics predict that therapeutic gain will also be very significant with new drugs and a substantial synergism between beam and compound qualities exists.
Bibliographic Reference: Article: Medical Physics
Record Number: 199711368 / Last updated on: 1997-10-23
Original language: en
Available languages: en